Hurley Capital’s Yarrow Bioscience YARW Stock Holding History

Hurley Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$365	Hold	11	–	–	﹤0.01%	626
2026 Q1	$335	Hold	11	–	–	﹤0.01%	624
2025 Q4	$325	Buy	+11	New	+$221	﹤0.01%	554

Other funds holding YARW

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

T3 Companies New York $93.7M AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $136M AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Hurley Capital's YARW Position: Q2 2026 in Review

Hurley Capital held its Yarrow Bioscience (YARW) position steady in Q2 2026 at 11 shares worth $365. The position accounts for ﹤0.01% of the portfolio, ranked #626.

Hurley Capital first reported a position in YARW in Q4 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

Hurley Capital held 11 shares of Yarrow Bioscience worth $365 as of Q2 2026.
Hurley Capital left its Yarrow Bioscience share count unchanged in Q2 2026.
Yarrow Bioscience made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #626 holding.
Hurley Capital first reported a position in Yarrow Bioscience in Q4 2025 and has held it in 3 quarters since.
40 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.